Scancell Holdings plc, („Scancell‟ or the „Company‟) the developer of novel immunotherapies for the
treatment of cancer, was informed on 11 July 2013 that one of the three patients recruited into the higher 8mg dose study of SCIB1 will no longer be eligible for evaluation due to delivery of an incomplete dose of SCIB1 following a fault with the electroporation device for that patient. Scancell will recruit a replacement patient as soon as possible in order to complete the initial phase of the 8mg study which is to assess the safety and immune response produced by the 8mg dose prior to expanding the study to include a further ten patients as planned. The initial part of the study is now expected to be completed early next year.
The higher 8mg dose SCIB1 study has been implemented for two reasons:
Richard Goodfellow, Joint CEO of Scancell, said:
“With the higher dose study underway, we are now looking to recruit a new patient to ensure adequate
safety and immune response data ahead of the extended trial of SCIB1 in patients with tumour load. We
firmly believe that the data we gain from this additional trial will add further value to SCIB1 and the
ImmunoBody® platform and look forward to reporting the results in due course.”
For Further Information:
Scancell Holdings Plc
Dr Richard Goodfellow, Joint CEO
Professor Lindy Durrant, Joint CEO
+ 44 (0) 74 2323 0 497
Cenkos Securities: +44 (0) 20 7397 8900
FTI Consulting +44 (0) 20 7831 3113
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody®
and Moditope™ technology platforms. Scancell‟s first ImmunoBody®, SCIB1 is being developed for the
treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study
showing that SCIB1 produced an immune response which might be associated with clinical benefit in
patients with malignant melanoma was released in December 2012.
Scancell‟s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune
system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic Tlymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of
killer CD4 T cells that destroy tumours without toxicity. The Directors believe that the Moditope™ platform could play a major role in the development of safe and effective cancer immunotherapies in the future.
After buying 77.56mln new shares at a price of 5p per share, which was a slight discount to the 5.35p closing price the previous day, the Vulpes Life Sciences Fund will have a 16.67% stake in the company.
Fri, 21 Jun 2019 08:21:00
Scancell Holdings PLC (LON:SCLP) CEO Cliff Holloway caught up with Proactive London's Andrew Scott following the announcement they'd raised £3.88mln via a placing with a single new investor to help fund the progression of its lead cancer asset into clinical trials.
The Vulpes Life Sciences Fund will now have a 16.67% stake in the company when the shares are issued next Monday.
Thu, 13 Jun 2019 09:53:00
“At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly.”
Thu, 13 Jun 2019 06:31:00
Sign up to our newsletter to stay up to date with Scancell